Analysis of thyroid function in rats specifically expressing MHC class II and B7.1 in the thyroid

甲状腺特异性表达MHC II类和B7.1的大鼠甲状腺功能分析

• 批准号: 12671076
• 负责人: ENDO Toyoshi
• 金额: $ 2.43万
• 依托单位: University of Yamanashi Faculty of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12671076/
• 关键词: Graves' disease; MHC class II antigen; B7.1; transgenic rat; thyroid stimulating antibody; T3; Transgenic rat; 眼球突出; TSHレセプター抗体; 遺伝子欠損マウス; hyt; hytマウス

In order to investigate the role of MHC class II antigen and co-stimulatory molecule, B7.1, in the pathogenesis of Graves' disease, we prepared thyroglobulin promoter derived class II transactivator gene (CIITA) and also B7.1 gene. We produced transgenic rats of these gene. No difference was observed in the serum T3 between CIITA transgenic and the control rats, and we could not observed thyroid stimulating antibody (TSAb) activity in the sera of these transgenic animals. We further obtained transgenic rats specifically expressing both MHC class II and B7.1 in the thyroid. However, no TSAb activity was also observed in these rats. These results indicate that co expression of thyrotropin receptor and MHC class II antigen in thyroid gland is not sufficient to produce TSAb.

为了研究MHC Ⅱ类抗原和共刺激分子B7.1在Graves病发病中的作用，我们制备了甲状腺球蛋白启动子衍生的Ⅱ类反式激活因子基因（CIITA）和B7.1基因。我们制造了这些基因的转基因老鼠。CIITA转基因大鼠与对照组大鼠血清T3水平无明显差异，转基因动物血清中未检测到甲状腺刺激抗体（TSAb）活性。我们进一步获得了在甲状腺中特异性表达MHC II类和B7.1的转基因大鼠。然而，在这些大鼠中也未观察到TSAb活性。这些结果表明，促甲状腺激素受体和MHC Ⅱ类抗原在甲状腺中的共表达不足以产生TSAb。

项目成果

K.Ohta,T.Endo,T.Onaya.: "Ligand for peroxisome proliferator-activated receptor inhibit growth and induce apotosis of human Papillary thyroid carcinoma cells."THE JOURNAL OF ENDOCRINOLOGY AND METABOLISM. (In press). (2001)

K.Ohta，T.Endo，T.Onaya.：“过氧化物酶体增殖物激活受体的配体抑制人乳头状甲状腺癌细胞的生长并诱导其凋亡。”内分泌学与代谢杂志。

Ikeda m. et al.: "Thyroid hormone increases peroxisome proliferator-activated receptor gene expression by potentiation of CCAAT enhancer binding protein-mediated transcription factor. submitted"Mol Endocrino. (印刷中).

Ikeda m. 等人：“甲状腺激素通过增强 CCAAT 增强子结合蛋白介导的转录因子来增加过氧化物酶体增殖物激活受体基因的表达。”Mol Endocrino（正在出版）。

H.Shimura,H.Suzuki,A.Miyazaki, et al.: "Transcriptional activation of thyroglobulin promoter directing suicide gene expression by thyroid Transcription factor-1 in thyroid cancer cells."CANCER RESEARCH. (In press). (2001)

H.Shimura、H.Suzuki、A.Miyazaki 等人：“甲状腺球蛋白启动子的转录激活通过甲状腺癌细胞中的甲状腺转录因子-1 指导自杀基因的表达。”癌症研究。

遠藤 登代志: "バセドウ病の発症機構と薬物療法・管理の基本戦略"Medica Practice. 19. 196-202 (2002)

Toyo Endo：“格雷夫斯病的发病机制和药物治疗和管理的基本策略”Medica Practice 19. 196-202 (2002)。

Kazuyasu O., et al.: "Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells"Clinical Endocrinology & Metabolism. 86(5). 2170-2177 (2001)

Kazuyasu O. 等人：“过氧化物酶体增殖物激活受体 γ 的配体抑制人乳头状甲状腺癌细胞的生长和诱导”临床内分泌学与代谢 86(5) (2001)。